nivolumab-avd vs brentuximab vedotin-avd in pediatric patients with chl: swog s1826 trial
Published 9 months ago • 204 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
1:41
swog s1826: nivolumab avd vs brentuximab vedotin avd for advanced stage hodgkin lymphoma
-
1:26
promising results from the swog s1826 trial: nivo-avd versus bv-avd in patients with chl
-
1:15
swog s1826: promising results with the combination of nivolumab-avd in hodgkin lymphoma
-
6:50
nivolumab-avd improved pfs versus brentuximab vedotin-avd in patients with advanced stage hl
-
3:04
nivahl: nivolumab and avd in early-stage unfavorable hl
-
1:08
nivolumab and brentuximab vedotin with or without bendamustine for r/r hodgkin lymphoma
-
2:18
sgn35-027: brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in hl
-
1:24
novel agents for the treatment of hodgkin lymphoma: brentuximab vedotin and nivolumab
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
4:33
brawm: bendamustine, rituximab and acalabrutinib for waldenström’s macroglobulinemia
-
6:45
nivolumab chemotherapy in previously untreated stage iii or iv hodgkin lymphoma
-
4:22
brentuximab vedotin-nivolumab alone and then with r-chp as frontline therapy for pmbcl
-
1:02
seven-year os analysis from echelon-1: brentuximab vedotin avd versus abvd in hodgkin lymphoma
-
6:45
brentuximab vedotin with nivolumab ± ipilimumab in r/r hl: outcomes with and without autosct
-
0:41
results of swog s1826 study, showing nivo-avd better than bv-avd in hodgkin's lymphoma patients
-
1:21
hodgkin lymphoma highlights from ash 2023: nivo-avd versus bv-avd in patients with hl
-
1:42
brentuximab vedotin after autosct in pediatric patients with r/r hodgkin lymphoma
-
1:14
brentuximab vedotin combined with nivolumab for hodgkin lymphoma
-
3:23
brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical hodgkin lymphoma
-
1:41
echelon-1 aya subgroup results: brentuximab vedotin plus avd vs. abvd
-
3:21
brentuximab vedotin nivolumab in lymphoma
-
5:06
5-year follow-up of echelon-1: brentuximab plus avd versus abvd in hodgkin lymphoma